Loading
Life sciences · Journal article
Kardiologia Polska · September 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Heart failure with preserved ejection fraction (HFpEF) is increasingly recognized as a heterogeneous syndrome in which ageing, hypertension, obesity, diabetes, chronic kidney disease, atrial fibrillation, coronary artery disease, and metabolic abnormalities interact with myocardial and vascular dysfunction.Beyond elevated left ventricular filling pressures and impaired relaxation, systemic inflammation, endothelial dysfunction, immune-cell activation, and myocardial fibrosis have emerged as potentially important components of HFpEF pathophysiology [1-3].The study by Stępień et al. [4], based on the Lesser Poland Cracovian Heart Failure Registry (LECRA-HF), adds an interesting perspective by examining whether commonly available immune-inflammatory biomarkers (IIBs) and statin therapy are related to long-term mortality in patients hospitalized with acute HFpEF.The principal finding is that the prognostic value of several inflammatory indices differed according to statin prescription status.